[Retracted] Antiviral Therapy with Entecavir following Antituberculosis Therapy Alleviates Liver Injury and Restores Innate Immunity in Tuberculosis Patients Coinfected with Hepatitis B Virus

Table 4

The numbers of intestinal microflora between the two groups before treatment and 6 months after treatment.

Group	Time	Bifidobacterium (lgCFU/g)	Lactobacillus (lgCFU/g)	Enterobacterium (lgCFU/g)	Enterococcus (lgCFU/g)	Clostridium (lgCFU/g)
Anti-TB group (n = 50)	Before treatment	8.23 ± 1.34	6.49 ± 1.32	9.17 ± 1.22	9.51 ± 1.31	10.15 ± 1.24
	6 months after treatment	9.19 ± 1.21	7.04 ± 1.01	8.37 ± 1.38	8.49 ± 1.25	9.26 ± 1.15
Antiviral group (n = 50)	Before treatment	8.26 ± 1.33	6.68 ± 1.25	9.18 ± 1.14	9.50 ± 1.29	10.14 ± 1.25
	6 months after treatment	10.15 ± 2.14	8.28 ± 1.31	7.25 ± 1.43	7.47 ± 1.19	8.42 ± 1.13
t/P (within the anti-TB group)		3.075/0.021	3.091/0.023	3.086/0.017	2.978/0.031	3.418/0.016
t/P (within the antiviral group)		4.395/0.013	4.197/0.011	4.394/0.008	4.068/0.009	5.148/0.002
t/P (between groups)		3.179/0.018	3.175/0.019	3.187/0.016	3.517/0.015	3.054/0.012